The global pharma industry is bringing new hope to patients around the world. High-cost biologic medicines pending patent expiration represent significant market opportunity for low cost alternatives, biosimilars.
Biosimilars are safe, effective and highly similar versions of approved and authorised biological medicines. They treat the same diseases as the reference biological medicine and with the same efficacy. The only difference is that biosimilar medicines are marketed only after the patent expiry of the reference biological medicine.
Biosimilars offer the potential to improve the quality of life for millions of patients while saving the healthcare system billions of dollars each year. They are affordable and indispensable in economies where expensive treatments are not available or financially feasible.